Management of the acute migraine headache.

As many as 30 million Americans have migraine headaches. The impact on patients and their families can be tremendous, and treatment of migraines can present diagnostic and therapeutic challenges for family physicians. Abortive treatment options include nonspecific and migraine-specific therapy. Nonspecific therapies include analgesics (aspirin, nonsteroidal anti-inflammatory drugs, and opiates), adjunctive therapies (antiemetics and sedatives), and other nonspecific medications (intranasal lidocaine or steroids). Migraine-specific abortive therapies include ergotamine and its derivatives, and triptans. Complementary and alternative therapies can also be used to abort the headache or enhance the efficacy of another therapeutic modality. Treatment choices for acute migraine should be based on headache severity, migraine frequency, associated symptoms, and comorbidities.

[1]  Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. , 1988, Cephalalgia : an international journal of headache.

[2]  J. Olesen,et al.  Epidemiology of headache in a general population--a prevalence study. , 1991, Journal of clinical epidemiology.

[3]  R. Lipton,et al.  Migraine in the United States: A review of epidemiology and health care use , 1993, Neurology.

[4]  B. Frishberg,et al.  The utility of neuroimaging in the evaluation of headache in patients with normal neurologic examinations , 1994, Neurology.

[5]  G. Gronseth,et al.  The utility of the electroencephalogram in the evaluation of patients presenting with headache , 1995, Neurology.

[6]  D. Yealy,et al.  Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. , 1995, Annals of emergency medicine.

[7]  J. Jones,et al.  Intramuscular prochlorperazine versus metoclopramide as single-agent therapy for the treatment of acute migraine headache. , 1996, The American journal of emergency medicine.

[8]  Moore Kl,et al.  Drug treatment of migraine: Part I. Acute therapy and drug-rebound headache. , 1997 .

[9]  Drug treatment of migraine: Part I. Acute therapy and drug-rebound headache. , 1997, American family physician.

[10]  C. Jackson.  Effective headache management. Strategies to help patients gain control over pain. , 1998, Postgraduate medicine.

[11]  W F Stewart,et al.  Burden of migraine in the United States: disability and economic costs. , 1999, Archives of internal medicine.

[12]  D. Faulds,et al.  Rizatriptan , 1999, Drugs.

[13]  Treatment of migraine headaches. , 1999, Mayo Clinic proceedings.

[14]  R. Cady,et al.  Diagnosis and treatment of migraine. , 2002, Clinical cornerstone.

[15]  H. Diener,et al.  Antimigraine drugs , 2020, Journal of Neurology.

[16]  N. Mathew,et al.  Treatment of Nonresponders to Oral Sumatriptan With Zolmitriptan and Rizatriptan: A Comparative Open Trial , 2000, Headache.

[17]  R. Lipton,et al.  Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial. , 2000, JAMA.

[18]  D. Matchar,et al.  Toward evidence-based management of migraine. , 2000, JAMA.

[19]  P R Saxena,et al.  Ergotamine in the acute treatment of migraine: a review and European consensus. , 2000, Brain : a journal of neurology.

[20]  S. Silberstein.  Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review) , 2000, Neurology.

[21]  E. Spierings,et al.  Naratriptan Efficacy in Migraineurs Who Respond Poorly to Oral Sumatriptan , 2000, Headache.

[22]  N. Ramadan,et al.  Evidence-Based Guidelines in the Primary Care Setting : Neuroimaging in Patients with Nonacute Headache , 2000 .